Logo image of XFOR

X4 PHARMACEUTICALS INC (XFOR) Stock Fundamental Analysis

NASDAQ:XFOR - US98420X1037 - Common Stock

3.64 USD
+0.52 (+16.67%)
Last: 9/4/2025, 5:53:07 PM
3.73 USD
+0.09 (+2.47%)
After Hours: 9/4/2025, 5:53:07 PM
Fundamental Rating

2

Taking everything into account, XFOR scores 2 out of 10 in our fundamental rating. XFOR was compared to 542 industry peers in the Biotechnology industry. XFOR may be in some trouble as it scores bad on both profitability and health. XFOR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XFOR had negative earnings in the past year.
In the past year XFOR has reported a negative cash flow from operations.
In the past 5 years XFOR always reported negative net income.
XFOR had a negative operating cash flow in each of the past 5 years.
XFOR Yearly Net Income VS EBIT VS OCF VS FCFXFOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of XFOR (-96.96%) is worse than 75.09% of its industry peers.
With a Return On Equity value of -2568.02%, XFOR is not doing good in the industry: 83.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -96.96%
ROE -2568.02%
ROIC N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
XFOR Yearly ROA, ROE, ROICXFOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

XFOR has a Gross Margin of 83.00%. This is amongst the best in the industry. XFOR outperforms 86.35% of its industry peers.
XFOR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XFOR Yearly Profit, Operating, Gross MarginsXFOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

XFOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XFOR has been increased compared to 1 year ago.
The number of shares outstanding for XFOR has been increased compared to 5 years ago.
XFOR has a worse debt/assets ratio than last year.
XFOR Yearly Shares OutstandingXFOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XFOR Yearly Total Debt VS Total AssetsXFOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -9.43, we must say that XFOR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.43, XFOR is not doing good in the industry: 71.22% of the companies in the same industry are doing better.
XFOR has a Debt/Equity ratio of 19.10. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of XFOR (19.10) is worse than 84.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 19.1
Debt/FCF N/A
Altman-Z -9.43
ROIC/WACCN/A
WACC11.93%
XFOR Yearly LT Debt VS Equity VS FCFXFOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

XFOR has a Current Ratio of 3.19. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.19, XFOR is doing worse than 62.18% of the companies in the same industry.
A Quick Ratio of 3.05 indicates that XFOR has no problem at all paying its short term obligations.
XFOR has a Quick ratio of 3.05. This is in the lower half of the industry: XFOR underperforms 60.70% of its industry peers.
Industry RankSector Rank
Current Ratio 3.19
Quick Ratio 3.05
XFOR Yearly Current Assets VS Current LiabilitesXFOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

XFOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.35%.
The Revenue has grown by 5721.31% in the past year. This is a very strong growth!
EPS 1Y (TTM)-12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.24%
Revenue 1Y (TTM)5721.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%250.44%

3.2 Future

XFOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.46% yearly.
Based on estimates for the next years, XFOR will show a very strong growth in Revenue. The Revenue will grow by 145.58% on average per year.
EPS Next Y76.99%
EPS Next 2Y36.44%
EPS Next 3Y23.99%
EPS Next 5Y14.46%
Revenue Next Year1518.99%
Revenue Next 2Y212.62%
Revenue Next 3Y271.06%
Revenue Next 5Y145.58%

3.3 Evolution

XFOR Yearly Revenue VS EstimatesXFOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
XFOR Yearly EPS VS EstimatesXFOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XFOR. In the last year negative earnings were reported.
Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XFOR Price Earnings VS Forward Price EarningsXFOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XFOR Per share dataXFOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

XFOR's earnings are expected to grow with 23.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.44%
EPS Next 3Y23.99%

More info and screens

0

5. Dividend

5.1 Amount

XFOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (9/4/2025, 5:53:07 PM)

After market: 3.73 +0.09 (+2.47%)

3.64

+0.52 (+16.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners52.93%
Inst Owner Change-96.85%
Ins Owners2.6%
Ins Owner Change9.91%
Market Cap41.53M
Analysts83.64
Price Target13.16 (261.54%)
Short Float %23.7%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.23%
Min EPS beat(2)21.58%
Max EPS beat(2)100.88%
EPS beat(4)2
Avg EPS beat(4)27.08%
Min EPS beat(4)-12.04%
Max EPS beat(4)100.88%
EPS beat(8)4
Avg EPS beat(8)-140.1%
EPS beat(12)6
Avg EPS beat(12)-99.51%
EPS beat(16)7
Avg EPS beat(16)-77.16%
Revenue beat(2)2
Avg Revenue beat(2)666.75%
Min Revenue beat(2)20.01%
Max Revenue beat(2)1313.49%
Revenue beat(4)3
Avg Revenue beat(4)325.24%
Min Revenue beat(4)-67.57%
Max Revenue beat(4)1313.49%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-64.36%
PT rev (3m)-73.67%
EPS NQ rev (1m)52.66%
EPS NQ rev (3m)58.29%
EPS NY rev (1m)49.66%
EPS NY rev (3m)56.35%
Revenue NQ rev (1m)1.19%
Revenue NQ rev (3m)-26.87%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)39.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.27
P/FCF N/A
P/OCF N/A
P/B 10.46
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.83
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-9.85
FCFYN/A
OCF(TTM)-9.58
OCFYN/A
SpS2.87
BVpS0.35
TBVpS-2.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.96%
ROE -2568.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83%
FCFM N/A
ROA(3y)-52.08%
ROA(5y)-58.87%
ROE(3y)-165.72%
ROE(5y)-148.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 19.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.52%
Cap/Sales 9.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.19
Quick Ratio 3.05
Altman-Z -9.43
F-Score1
WACC11.93%
ROIC/WACCN/A
Cap/Depr(3y)318.09%
Cap/Depr(5y)293.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65.24%
EPS Next Y76.99%
EPS Next 2Y36.44%
EPS Next 3Y23.99%
EPS Next 5Y14.46%
Revenue 1Y (TTM)5721.31%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%250.44%
Revenue Next Year1518.99%
Revenue Next 2Y212.62%
Revenue Next 3Y271.06%
Revenue Next 5Y145.58%
EBIT growth 1Y14.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.59%
OCF growth 3YN/A
OCF growth 5YN/A